Individual Patient Expanded Access Investigation New Drug (IND) Application for Administration of Autologous Human Adipose-Derived Mesenchymal Stem Cells in Alzheimer's Disease
Latest Information Update: 18 May 2022
At a glance
- Drugs Adipose-derived autologous mesenchymal stem cell therapy-Celltex Therapeutics (Primary)
- Indications Alzheimer's disease
- Focus Expanded access; Therapeutic Use
- Sponsors Celltex Therapeutics
- 03 May 2022 Status changed from recruiting to active, no longer recruiting.
- 30 Apr 2021 New trial record